Skip to main content

Main menu

  • Home
  • About
    • About CBM
    • Editorial Board
    • Announcement
  • Articles
    • Ahead of print
    • Current Issue
    • Archive
    • Collections
    • Cover Story
  • For Authors
    • Instructions for Authors
    • Resources
    • Submit a Manuscript
  • For Reviewers
    • Become a Reviewer
    • Instructions for Reviewers
    • Resources
    • Outstanding Reviewer
  • Subscription
  • Alerts
    • Email Alerts
    • RSS Feeds
    • Table of Contents
  • Contact us
  • Other Publications
    • cbm

User menu

  • My alerts

Search

  • Advanced search
Cancer Biology & Medicine
  • Other Publications
    • cbm
  • My alerts

Cancer Biology & Medicine

Advanced Search

 

  • Home
  • About
    • About CBM
    • Editorial Board
    • Announcement
  • Articles
    • Ahead of print
    • Current Issue
    • Archive
    • Collections
    • Cover Story
  • For Authors
    • Instructions for Authors
    • Resources
    • Submit a Manuscript
  • For Reviewers
    • Become a Reviewer
    • Instructions for Reviewers
    • Resources
    • Outstanding Reviewer
  • Subscription
  • Alerts
    • Email Alerts
    • RSS Feeds
    • Table of Contents
  • Contact us
  • Follow cbm on Twitter
  • Visit cbm on Facebook

Latest Articles

  • Open Access
    Immunotherapy rechallenge of patients with advanced NSCLC progression after sequential treatment with third-generation EGFR-TKI and immunotherapy
    Shuyi Hu, Zipeng Wu, Yingying Dai, Xinhong Shi, Qin Hu, Caolu Liu, Yifei Zhu, Ruofan Yu, Jingwen Li, Ying Liu, Tianyi Liu, Lin Lu, Chengyun Yao, Bo Shen, Meiqi Shi, Cheng Chen, Xiaohua Wang and Guoren Zhou
    Cancer Biology & Medicine December 2025, 20250393; DOI: https://doi.org/10.20892/j.issn.2095-3941.2025.0393
  • Open Access
    Harnessing the power of cancer-associated fibroblasts to revolutionize pancreatic cancer treatment
    Jian Shen, Ruopu Wu, Tao Yin, Qun Wang and Lei Nie
    Cancer Biology & Medicine December 2025, 20250288; DOI: https://doi.org/10.20892/j.issn.2095-3941.2025.0288
  • Open Access
    Tumor microenvironment-responsive polymeric nanoparticles for enhanced immunotherapy
    Yongxin Zhang, Shaobing Zhou and Jingya Zhao
    Cancer Biology & Medicine December 2025, 20250517; DOI: https://doi.org/10.20892/j.issn.2095-3941.2025.0517
  • Open Access
    From residual risk to precision intervention: the evolving role of minimal residual disease in breast cancer management
    Junnan Xu, Kun Fang, Xiaoxi Li, Li Han, Shulan Sun and Tao Sun
    Cancer Biology & Medicine November 2025, 20250431; DOI: https://doi.org/10.20892/j.issn.2095-3941.2025.0431
  • Open Access
    Enhancing cancer immunotherapy through polymer-based antibody conjugation technologies
    Hongyu Chu, Jun Chen, Sheyu Ye, Xuedong Fang, Na Shen and Zhaohui Tang
    Cancer Biology & Medicine November 2025, 20250512; DOI: https://doi.org/10.20892/j.issn.2095-3941.2025.0512
  • Open Access
    Primary cilia in cancer: structures, functions, mechanisms, and therapeutic implications
    Miaomiao Zheng, Jun Zhou and Yijie Wang
    Cancer Biology & Medicine November 2025, 20250340; DOI: https://doi.org/10.20892/j.issn.2095-3941.2025.0340
View more latest articles

Cover Story

Current issue

Cancer Biology & Medicine: 22 (11)
Cancer Biology & Medicine
Vol. 22, Issue 11
15 Nov 2025
  • Table of Contents
  • Index by author

Submit

  • Top Topics
  • Most Cited
  • Most Read
Loading
The advanced development of molecular targeted therapy for hepatocellular carcinoma
The efficacies and biomarker investigations of anti-programmed death-1 (anti-PD-1)-based therapies for metastatic bone and soft tissue sarcoma
Immunology and immunotherapy in breast cancer
Effects of menopausal hormone therapy-based on the role of estrogens, progestogens, and their metabolites in proliferation of breast cancer cells
Breast cancer screening and early diagnosis in Chinese women
Is adjuvant chemotherapy necessary for early gastric cancer?
Modulating microRNAs in cancer: next-generation therapies
Safety and efficacy of anti-EGFR monoclonal antibody (SCT200) as second-line therapy in advanced esophageal squamous cell carcinoma
Personalized immunotherapy in cancer precision medicine
Cellular immunotherapy for hematological malignancy: recent progress and future perspectives
Back to top

Navigate

  • Home
  • Current Issue

More Information

  • About CBM
  • About CACA
  • About TMUCIH
  • Editorial Board
  • Subscription

For Authors

  • Instructions for authors
  • Journal Policies
  • Submit a Manuscript

Journal Services

  • Email Alerts
  • Facebook
  • RSS Feeds
  • Twitter

 

© 2025 Cancer Biology & Medicine

Powered by HighWire